Filing Flows › Health Care › Pmgc Holdings (ELAB)
Pmgc Holdings (ELAB) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Pmgc Holdings (ELAB) Q2 2026 earnings results →
Q2 2026 225¢ of every $1 of revenue lost · operating margin -225.1%
Pmgc Holdings made $1.3M in Q2 2026. Operating margin -225.1%, net loss $2.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.3M in Q2 2026, up 92% from the previous quarter.
Gross margin was 29.5%. Operating costs exceeded revenue by $2.9M, an operating margin of -225.1%. The quarter ended with a net loss of $2.9M, narrower than the previous quarter's $5.0M loss.
Operating cash flow was −$2.0M. Non-cash charges added back $281K of depreciation and amortization and $175K of share-based compensation. Working capital and other items added $498K. Capital expenditures of −$28K exceeded it, leaving free cash flow of −$2.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $1.3M | — | -225.1% | −$2.9M | −$2.0M |
| Q1 2026 | 10-Q | May 15, 2026 | $682K | — | -728.3% | −$5.0M | −$3.0M |
| Q4 2025 | 10-K | Mar 30, 2026 | $304K | — | -980.7% | −$3.0M | −$1.8M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $286K | -46% | -769.0% | −$2.6M | −$1.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Pmgc Holdings
As of December 31, 2025, we manage and operate a diverse portfolio of four (4) wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors: We are dedicated to enhancing our portfolio through the acquisition of operating companies and innovative biotechnology assets that align with our growth mission, while actively pursuing the acquisition of operating companies.
In its own words, from its 10-K, filed Mar 30, 2026.
Pmgc Holdings against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -225.1% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ELAB Pmgc Holdings | Q2 2026 | $1.3M | — | -225.1% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Pmgc Holdings 10-Q on SEC EDGAR · CIK 1840563 · Pharmaceutical Preparations
More on ELAB
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results